MDM2 proto-oncogene has an alarming and important function that promotes MYCN proto-oncogene expression

Scientists at the Sabang Institute at the Children's Hospital of California have recently discovered that the MDM2 proto-oncogene has an alarming and important function that promotes MYCN proto-oncogene expression. The study was published on October 17 on Oncogene, which also published some other studies on recombinant human proteins.

Retinoblastoma is a retinal neoplasm in children 1 to 2 years old. Although the incidence is low, if not treated, it can cause fatal or blinding serious consequences. This tumor also plays a special role in the study of cancer because its lesion progression is found to be associated with mutations or deletions of a single gene, RB1.

The MDM2 gene has been thought to be involved in the development of tumors because it promotes the transformation of normal cells into cancer cells. This function is thought to be associated with a tumor suppressor protein p53 that inhibits apoptosis which leads to aberrant proliferation.

MDM2 also plays an important role in other p53-independent signaling pathways. This protein, called MYCN, is regulated by MDM2 and plays an important role in cell proliferation. In the presence of this protein, retinoblastoma can grow by 20% to 25%, leading to secondary disease and poor prognosis. Although MYCN has the potential to be a therapeutic target, it is difficult to be blocked by a single small molecule. The findings of this study provide the theoretical support for the regulation of MYCN expression by targeting MDM2.

This study first elucidates that retinoblastoma is more dependent on MDM2 than on MDM4 which is another member of this family. Flarebio offers recombinant proteins of good quality such as recombinant CDH4 at competitive prices.